Cheever K L, DeBord D G, Swearengin T F
Department of Health and Human Services, National Institute for Occupational Safety and Health, Cincinnati, Ohio 45226.
Fundam Appl Toxicol. 1991 Jan;16(1):71-80. doi: 10.1016/0272-0590(91)90136-r.
The effect of multiple oral administration of MOCA, a suspect human carcinogen, was studied in the adult male rat. As many as 28 consecutive daily doses of [14C]MOCA at 28.1 mumol/kg body wt (5 microCi/day) were administered and rats were euthanized at weekly intervals for 7 weeks. MOCA adduct formation for globin and serum albumin was evaluated by determination of [14C]MOCA covalent binding. The covalent binding associated with globin showed a linear increase over the 28-day exposure period with 342 fmol/mg globin 24 hr after the final dose. More extensive covalent binding was detected for albumin with 443 fmol/mg albumin after the final dose, but increases were not linear. After cessation of dosing, the albumin adduct levels decreased rapidly (t1/2 = 4.6 days) in relation to globin adduct levels (t1/2 = 16.1 days). The MOCA-globin adduct t1/2 is consistent with that determined after a single 281 mumol/kg oral dose of MOCA. Significant differences related to route of administration were detected for 24-hr globin covalent binding with ip greater than po greater than dermal. Distribution of undifferentiated [14C]MOCA was highest in the liver at 24 hr with tissue levels for liver greater than kidney greater than lung greater than spleen greater than testes greater than urinary bladder. Induction of cytochrome P450 enzymes by administration of phenobarbital (100 mg/kg/day/3 days) resulted in a significant (p less than 0.05) increase in MOCA-globin adduct formation detected with 33.5 pmol/mg globin for induced rats versus 13.6 pmol/mg globin for control rats. Although MOCA-globin and albumin adducts show differing stability, quantification of such MOCA adducts may be useful for long-term industrial biomonitoring of MOCA.
在成年雄性大鼠中研究了多次口服可疑人类致癌物 4,4'-亚甲基双(2-氯苯胺)(MOCA)的效果。连续 28 天每天按 28.1 μmol/kg 体重(5 μCi/天)给予[14C]MOCA,并在 7 周内每周对大鼠实施安乐死。通过测定[14C]MOCA 共价结合来评估球蛋白和血清白蛋白的 MOCA 加合物形成情况。与球蛋白相关的共价结合在 28 天的暴露期内呈线性增加,末次给药后 24 小时为 342 fmol/mg 球蛋白。白蛋白检测到更广泛的共价结合,末次给药后为 443 fmol/mg 白蛋白,但增加不是线性的。停止给药后,白蛋白加合物水平相对于球蛋白加合物水平(t1/2 = 16.1 天)迅速下降(t1/2 = 4.6 天)。MOCA-球蛋白加合物的 t1/2 与单次口服 281 μmol/kg MOCA 后测定的结果一致。检测到与给药途径相关的显著差异,腹腔注射大于口服大于经皮给药 24 小时球蛋白共价结合情况。24 小时时未分化的[14C]MOCA 在肝脏中的分布最高,组织水平为肝脏大于肾脏大于肺大于脾脏大于睾丸大于膀胱。给予苯巴比妥(100 mg/kg/天/3 天)诱导细胞色素 P450 酶导致检测到的 MOCA-球蛋白加合物形成显著增加(p < 0.05),诱导大鼠为 33.5 pmol/mg 球蛋白,对照大鼠为 13.6 pmol/mg 球蛋白。尽管 MOCA-球蛋白和白蛋白加合物显示出不同的稳定性,但此类 MOCA 加合物的定量对于 MOCA 的长期工业生物监测可能有用。